FLT4 Fc Human

Vascular Endothelial Growth Factor Receptor-3 Fc Chimera Human Recombinant
Cat. No.
BT21672
Source
Insect Cells.
Synonyms
Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-LIKE TYROSINE KINASE 4, VEGFR-3.
Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Purity
Greater than 90.0% as determined by(a)Analysis by RP-HPLC.
(b)Analysis by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

Soluble FLT4 Human Recombinant fused with the Fc part of human IgG1 produced in baculovirus is a monomeric, glycosylated, polypeptide containing 774 amino acids and having a molecular mass of 260 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The FLT4 Fc Chimera is purified by proprietary chromatographic techniques.

Product Specs

Introduction
VEGFR-1, VEGFR-2, and VEGFR-3 are receptor tyrosine kinases (RTKs) distinguished by seven immunoglobulin-like loops within their extracellular domain. These receptors are primarily found in hematopoietic precursor cells, vascular and lymphatic endothelial cells, and monocyte/macrophage lineage. They are essential for vasculogenesis, hematopoiesis, angiogenesis, and lymphangiogenesis. The FLT-4 cDNA encodes a precursor protein of 1298 amino acids, including a 23 amino acid signal peptide. Mature VEGFR-3/FLT-4 consists of a 751 amino acid extracellular domain, a 22 amino acid transmembrane domain, and a 482 amino acid cytoplasmic domain. VEGF-C and VEGF-D, members of the VEGF family, bind to and activate VEGFR-3/FLT-4. While the Flt-4 gene is widely expressed in the early embryo, its expression becomes restricted to lymphatic endothelial cells during later developmental stages, highlighting its crucial role in lymphangiogenesis.
Description
Soluble FLT4 Human Recombinant, fused with the Fc region of human IgG1 and produced in a baculovirus expression system, is a monomeric, glycosylated polypeptide. This protein comprises 774 amino acids and has a molecular weight of 260 kDa. The soluble receptor encompasses only the first seven extracellular domains, which are sufficient for ligand binding. Purification of the FLT4 Fc Chimera is achieved through proprietary chromatographic methods.
Physical Appearance
Sterile Filtered White lyophilized powder.
Formulation
FLT4 Fc Chimera was lyophilized from a sterile solution at a concentration of 1 mg/ml. The formulation contains no additives.
Solubility
To reconstitute the lyophilized FLT4 Fc Chimera, it is recommended to dissolve it in sterile water at a minimum concentration of 100 µg/ml. This reconstituted solution can be further diluted in other aqueous solutions as needed.
Stability
Lyophilized FLT4 remains stable at room temperature for up to 3 weeks. However, for long-term storage, it is recommended to store the lyophilized product desiccated at a temperature below -18°C. After reconstitution, FLT4 should be stored at 4°C for 2-7 days. For extended storage, the reconstituted solution should be kept at temperatures below -18°C. To ensure optimal stability during long-term storage, the addition of a carrier protein (0.1% HSA or BSA) is advised. Repeated freeze-thaw cycles should be avoided to maintain protein integrity.
Purity
Purity exceeds 90.0% as determined by: (a) Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) analysis and (b) Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) analysis.
Biological Activity
Biological activity is assessed based on the protein's ability to bind to recombinant rat VEGF-C in a functional solid phase binding assay. When immobilized at a concentration of 5 µg/ml, recombinant human VEGFR-3/FLT-4 demonstrates the capacity to bind recombinant rat VEGF-C within a linear range of 8-500 ng/ml.
Synonyms
Tyrosine-protein kinase receptor FLT4, PCL, FLT41, FMS-LIKE TYROSINE KINASE 4, VEGFR-3.
Source
Insect Cells.

Product Science Overview

Introduction

Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3), also known as Flt-4, is a crucial receptor in the vascular endothelial growth factor (VEGF) family. It plays a pivotal role in the development and maintenance of the lymphatic system. The VEGFR-3 Fc Chimera (Human Recombinant) is a fusion protein that combines the extracellular domain of VEGFR-3 with the Fc region of human IgG1. This chimera is used extensively in research to study lymphangiogenesis and related processes.

Structure and Function

The VEGFR-3 Fc Chimera is a disulfide-linked homodimeric protein. It consists of the VEGFR-3 receptor fused with a 6X histidine-tagged Fc portion of human IgG1 by a polypeptide linker . This structure allows the chimera to act as a specific marker for lymphatic vessels and plays a critical role in the development of the lymphatic vessel system.

VEGFR-3 is a tyrosine-protein kinase that acts as a cell-surface receptor for VEGF-C and VEGF-D. It is essential for adult lymphangiogenesis and the development of the vascular network and cardiovascular system during embryonic development . The receptor promotes the proliferation, survival, and migration of endothelial cells and regulates angiogenic sprouting.

Role in Research and Therapeutics

The VEGFR-3 Fc Chimera is widely used in research to study the mechanisms of lymphangiogenesis and angiogenesis. It is particularly valuable in understanding the VEGF-C/VEGFR-3 signaling pathway, which is crucial for the formation of new lymphatic vessels from preexisting ones . This pathway is also implicated in various pathological conditions, including cancer, where it promotes tumor metastasis by enhancing lymphangiogenesis and angiogenesis inside and around tumors .

In therapeutic applications, the VEGFR-3 Fc Chimera holds promise for controlling and regressing lymphatic vessel-based dysfunctions. For instance, overexpression of soluble VEGFR-3 (sVEGFR-3) has been shown to enhance corneal transplant survival by blocking lymphangiogenesis and hemangiogenesis . This makes it a potential candidate for protecting the injured cornea from opacification secondary to infection, inflammation, or transplant rejection.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

FLT4 Human
Vascular Endothelial Growth Factor Receptor-3 Human Recombinant
Cat. No.
BT21777
Source
Insect Cells.
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.